Colchicine or
Phase 3Small molecule
Colchicine or is one of 52 small molecule programs targeting Injury. It is currently in Phase 3.
3
Indications
9
Total Trials
3
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Acute Coronary Syndrome
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Leqvio
NovartisApproved
Zyloprim
Jazz PharmaceuticalsApproved
Fragmin
PfizerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Coronary Syndrome1 trial
Treatment of ACuTe Coronary Syndromes With Low-dose colchICine
Recruiting·—·N/A·NCT06215989·6,574 enrolled
4 more indications
Intracranial Hemorrhages1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Colchicine or. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNYU Langone Health